

Atezolizumab IMpassion130

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



No QoL benefit



Serious and disabling adverse effects



Other adjustments



Atezolizumab IMpassion130

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Treatment of patients with unresectable locally advanced or metastatic TNBC whose tumours have PD-L1 expression  $\geq 1\%$  and who have not received prior ChT for metastatic disease  
Experimental Arm: Atezolizumab + Nab-paclitaxel  
Control Arm: Placebo + nab-paclitaxel

